Timothy Riley, PhD
Tim Riley is a highly respected and seasoned professional with wide-ranging background in the pharmaceutical and biotechnology industry, as well as significant business development experience. He brings to RSRT a passion for translational research that can impact lives and expertise in rare disease therapeutics, among many other relevant areas. Riley’s thirty-year track record in the pharmaceutical industry includes multiple approved and clinical stage drugs and successful leadership of high-performing research teams.
Dr. Riley is currently market sector leader for Mass General Brigham Innovation where he is responsible for commercializing intellectual property and therapeutic programs from $1.8 billion in research funding from Mass General, Brigham and Women’s and other Harvard Medical School associated research hospitals. He is also an Entrepreneur-in-residence at Yale University, where he is a strategic advisor for the translation of basic research programs to pharmaceutical applications.
He has also served as Associate Vice Chancellor for Innovation & Business Development at the University of Massachusetts Medical School, where he played a critical role in facilitating relationships among researchers, investors, and industry. Riley had a decade-long tenure at Nektar Therapeutics. His achievements there included working with the FDA to Fast Track therapeutics, leading a research team of 85 scientists for development of focused medicinal chemistry, and coordinating internal and external international relationships. He also co-founded a target validation company, linking genes to their importance in disease.
Dr. Riley holds a BS in chemistry and a PhD in organic chemistry-biochemistry emphasis from Brigham Young University. His therapeutic and technical areas of expertise include rare diseases, polymer technologies, large molecules, peptides and proteins, and small molecules.